This book covers all aspects of childhood leukemia. It examines genomic approaches to risk stratification and the use of risk-adjusted treatment approaches. The book also details promising targeted agents and strategies for the development of new agents.

This book is a comprehensive and up-to-date compendium on all aspects of childhood leukemia. After introductory chapters on the epidemiology and biology of pediatric leukemia, treatment considerations are extensively reviewed, with emphasis on the use of risk-adjusted treatment approaches. Promising targeted agents are discussed, and strategies for the development of new agents are appraised. The late effects of leukemia and its therapy are then considered in depth, with due attention to management of the psychosocial impact of the disease. Finally, global strategies to improve leukemia care and outcome are reviewed, and future directions discussed. The authors are internationally recognized experts and offer a largely evidence-based consensus on etiology, biology, and treatment. This handbook has far-reaching applicability to the clinical diagnosis and management of pediatric leukemia and will prove invaluable to specialists, generalists, and trainees alike.

Comprehensive and up-to-date compendium on the biology, diagnosis, and treatment of childhood leukemia Focuses especially on genomic approaches to risk stratification and the use of risk-adjusted treatment approaches Includes detailed discussion of promising targeted agents and strategies for the development of new agents Will prove invaluable to specialists, generalists, and trainees alike Includes supplementary material: sn.pub/extras

Autorentext
Gregory H. Reaman, M.D., is Chair of the Children's Oncology Group (COG) since its inception in 2000 resulting from the merger of four legacy pediatric cancer research organizations, is comprised of over 200 member institutions, dedicated to clinical, translational, and epidemiology research in childhood cancer. Dr. Reaman is a Professor of Pediatrics at The George Washington University School of Medicine and Health Sciences and a member of the Division of Hematology-Oncology at the Children's National Medical Center in Washington, D.C., which he directed for nearly 18 years, and Executive Director Emeritus of the Center for Cancer and Blood Disorders. Dr. Reaman serves or has served on the Editorial Boards of Leukemia, Journal of Clinical Oncology, Journal of Pediatric Hematology/Oncology, Pediatric Blood and Cancer, The Oncologist, Cancer, and Physicians Data Query (PDQ), National Cancer Institute as well as the ASCO Cancer Foundation's www.cancer.net. He has served as an Associate Editor of Cancer and Leukemia and Lymphoma. Previously, he served on the Board of Directors of the American Cancer Society and chaired its Task Force on Children and Cancer. Dr. Reaman served on the Board of Directors of the American Society of Clinical Oncology and has served on the ASCO Patient Education Committee, the Education and Program Committees, the Grant Selection Committee, and was the Chair of the ASCO Membership Committee. Also, he was a member of the Food and Drug Administration's Oncologic Drugs Advisory Committee and continues as a member of its Pediatric Subcommittee. He was a member of the NIH Roadmap Working Group. Additionally, he is a member of the Alliance for Childhood Cancer, a member of the Data Safety Monitoring Board of the National Cancer Institute's Clinical Oncology Program, and a member of the NCI's Translational Research Working Group. He is the author of more than 250 peer-reviewed manuscripts resulting from long-standing interests inacute leukemia biology and treatment and development of new drugs for pediatric cancer. Franklin O. Smith, III, M.D., is Vice-Chair of the Children's Oncology Group (COG). The COG, since its inception in 2000 resulting from the merger of four legacy pediatric cancer research organizations, is comprised of over 200 member institutions, dedicated to clinical, translational, and epidemiology research in childhood cancer. Dr. Smith is the Marjory J. Johnson Professor of Pediatrics at the University of Cincinnati College of Medicine. He has been the Director of the Division of Hematology/Oncology at Cincinnati Children's Hospital Medical Center (CCHMC) since 2001. He also serves as the Director of the Pediatric Hematology/Oncology Fellowship Training Program at CCHMC. Dr. Smith serves or has served on the Editorial Boards of Blood, the British Journal of Haematology, the Journal of Hematotherapy and Stem Cell Research, and Physicians Data Query (PDQ), National Cancer Institute. He has served as a Section Editor of Cancer Research Therapy and Control, Editor for Medscape General Medicine, Topics in Pediatric Leukemia, and currently serves as Editor of Case Reports in Medicine. Previously, he served on the Board of Directors and as Treasurer of the Foundation for the Accreditation of Cellular Therapies (FACT). Additionally, he is a member of the Sickle Cell Data Safety Monitoring Board of the National Heart, Lung and Blood Institute. He is the author of more than 100 peer-reviewed manuscripts.

Inhalt
Part 1: Genetics and the Epidemiology of Leukemia in Children: Epidemiology of Childhood Acute Leukemia .- Part 2: Biology of Pediatric Leukemia: Biology of Lymphoblastic Leukemia.-Biology of Acute Myeloid Leukemia.- Part 3: Treatment Considerations in Childhood Leukemia: Classification and Treatment of Acute Lymphoblastic Leukemia.-Acute Myeloid Leukemia.- Part 4: The Impact of Pharmacogenetics and Pharmacogenomics of Childhood Leukemia: Pharmacogenetics and Pharmacogenomics Considerations in the Biology and Treatment of Childhood Leukemia:.- Part 5: The Potential Role of Biologically Targeted Therapy for Childhood Leukemia: Promising Targeted Agents.-Strategies for New Agent Development and Clinical Trial Considerations.- Part 6: Late Effects of Leukemia and Its Therapy: 9. Late Sequelae in Children with Acute Lymphoblastic Leukemia: Impact on Long-term Survival and Quality of Life.- Acute Toxicities and Late Sequelae and Survivorship in children with AML: Impact of Allogeneic Stem Cell Transplant.- Part 7: Psychosocial Implications of Acute Leukemia Diagnosis and Treatment for Children and Families: Appreciation and the Interdisciplinary Management of the Psychosocial Impact of Leukemia on Children and Their Families.- Part 8: Global Strategies to Improve Leukemia Care and Outcome for Children: Improved Outcome for Children with Acute Leukemia: How to Address Global Disparities.-Part 9: Perspectives and Future Direction: Future Challenges and Opportunities to Improve Outcomes for Children with Leukemia.